TD Asset Management Inc. Has $135.36 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

TD Asset Management Inc. lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 7.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 519,339 shares of the medical research company’s stock after selling 43,508 shares during the period. TD Asset Management Inc.’s holdings in Amgen were worth $135,361,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in Amgen by 29.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,021 shares of the medical research company’s stock worth $329,000 after purchasing an additional 231 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Amgen by 21.3% in the 3rd quarter. Fisher Asset Management LLC now owns 102,352 shares of the medical research company’s stock valued at $32,979,000 after buying an additional 17,974 shares in the last quarter. DRW Securities LLC bought a new position in Amgen during the 3rd quarter worth $244,000. Loomis Sayles & Co. L P lifted its holdings in shares of Amgen by 6.6% during the third quarter. Loomis Sayles & Co. L P now owns 854 shares of the medical research company’s stock worth $275,000 after buying an additional 53 shares in the last quarter. Finally, Qsemble Capital Management LP bought a new stake in shares of Amgen in the third quarter valued at about $230,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent research reports. Leerink Partners lowered their price target on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Bank of America lifted their price target on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research report on Wednesday, March 5th. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Redburn Partners dropped their price objective on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $314.04.

Insider Transactions at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $306.86 on Wednesday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $164.85 billion, a P/E ratio of 40.64, a PEG ratio of 2.63 and a beta of 0.53. The company has a fifty day moving average price of $298.92 and a 200-day moving average price of $298.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.10%. Amgen’s payout ratio is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.